Error loading player: No playable sources found
CSC1
The Current State of 340B: The Impact on Health Centers and Why Advocacy Matters
Date
August 28, 2022
Explore related products in the following collection:
This session will provide health centers with a general update on the 340B drug pricing program that includes the topics of litigation status, manufacturer restrictions, and any anticipated regulatory challenges related to the program. Given the current status of the program, attendees will be given advocacy tools to employ to help defend the program at the state and federal levels.
Learning Objectives
- Understand the status of pending 340B litigation.
- Understand manufacturer restriction updates on the 340B program.
- Identify key issues plaguing the 340B program and what the future outlook is for the program.
Speakers
Tim Mallett, RPh, 340B ACE
Vice President of Pharmacy Services and NACHC 340B Consultant, 340Basics
Jason Reddish, JD
Partner, Feldesman Tucker Leifer Fidell LLP
Moderator
Associate Vice President, Policy & Regulatory Affairs, NACHC
Related Products
General Session
Kimberly Chang, MD, Vice-Speaker of the House, NACHC Board of Directors, Master of Ceremonies Welcome Rachel Gonzales-Hanson, Interim President and CEO, NACHC #ValueCHCs - Working and Winning Together Joe Dunn, Senior Vice President, Public Policy and Research, NACHC Vacheria Keys, Esq…
How Optimizing Lab Testing Can Benefit Your CHC - SPECIAL EXHIBITOR SESSION SPONSORED BY MCKESSON
Join the director of MedSol’s Laboratory Consultant team as she sheds light on the unique challenges that can come along with laboratory testing…
